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Introduction. Although increasing access to family planning has been an important part of the global development agenda, millions
of women continue to face unmet need for contraception.Materials andMethods. We analyzed data from a repeated cross-sectional
community survey conducted in Lusaka, Zambia, over an eight-year period.We described prevalence of modern contraceptive use,
including long-acting reversible contraception (LARC), among female heads of household aged 16–50 years. We also identified
predictors of LARC versus short-term contraceptive use among women using modern methods. Results and Discussion. Twelve
survey rounds were completed between November 2004 and September 2011. Among 29,476 eligible respondents, 17,605 (60%)
reported using modern contraception. Oral contraceptive pills remained the most popular method over time, but use of LARC
increased significantly, from less than 1% in 2004 to 9% by 2011 (𝑝 < 0.001). Younger women (OR: 0.46, 95% CI: 0.34, 0.61) and
women with lower levels of education (OR: 0.70, 95% CI: 0.56, 0.89) were less likely to report LARC use compared to women using
short-term modern methods. Conclusions. Population-based assessments of contraceptive use over time can guide programs and
policies. To achieve reproductive health equity and reduce unmet contraceptive need, future efforts to increase LARC use should
focus on young women and those with less education.
1. Introduction
Family planning (FP) can help individuals and couples attain
their desired number of children while providing benefits
across a range of areas in women’s reproductive health [1].
Since the 1994 International Conference on Population and
Development, national governments, international agencies,
and donor organizations have redoubled efforts to ensure that
FP services are universally available in Sub-Saharan Africa
and elsewhere [2, 3]. In 2012 alone, it was estimated that
218 million pregnancies were prevented. In that same year,
however, over 220 million women in the developing world
still had an unmet need for contraception [4].
Currently, efforts to expand FP access have focused on
increasing uptake of long-acting reversible contraception
(LARC) [5, 6]. Highly efficacious and safe, LARC includes
both subdermal implants and intrauterine contraceptive
devices (IUDs) [7]. These methods are user-independent,
reversible, and discreet. They do not require recurrent visits
to maintain efficacy and ensure a level of privacy [7, 8].
Monitoring use of contraceptive methods, such as LARC, is
critical to ongoing efforts to expand FP services. To date,
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however, most assessments have relied on sporadically and
inconsistently collected data or older mathematical models
[9, 10]. Population-level field data are urgently needed to
inform and optimize FP service implementation and policy.
2. Materials and Methods
We conducted a secondary analysis of a repeated cross-
sectional population-based survey to describe contraceptive
use among women in Lusaka, Zambia. The original survey
was designed to evaluate the impact of antiretroviral therapy
scale-up on population-level mortality in a setting of high
HIV prevalence. The methodology and primary outcomes
of the survey have been detailed elsewhere [11, 12]. Briefly,
between 2004 and 2011, we conducted 12 rounds of household
surveys across Lusaka District, which includes Zambia’s
capital city Lusaka. From each of the district’s 24 clinic catch-
ments areas, 150 households were randomly sampled, for a
total of 3,600 households per survey round. Fieldworkers
asked a household member to identify the household head
or heads. Interviewers were instructed to preferentially select
female household heads because they would be more likely
to recall details around household composition and events in
the past 12 months. Household heads were questioned about
sociodemographic characteristics, current contraceptive use
or reasons for nonuse, health-related decision-making, HIV
risk perception and testing history, and physical house-
hold characteristics and assets. Interviewers and partici-
pants completed all study procedures in English, Nyanja, or
Bemba. Each study respondent provided written informed
consent. This study was reviewed and approved by the
ethical review committees from the University of Zambia
Biomedical Research Ethics Committee (Lusaka, Zambia)
and theUniversity ofNorthCarolina (ChapelHill, NC,USA).
Our analysis was restricted to female household heads
aged 16–50 years who reported not being pregnant, not being
posthysterectomized, or not being postmenopausal. Male
household heads were excluded from the analysis. Women
who sought to delay or avoid pregnancy were asked about the
specific methods they were using. Those who were not using
any method of contraception were asked the main reasons
behind this decision, and all reasons from each respon-
dent were tabulated. In our analysis, contraceptive methods
were categorized as modern versus traditional methods and,
among those using modern contraception, we further cate-
gorized contraceptive methods into LARC or highly effective
short-term reversible methods [7]. Modern contraception
was defined as oral contraceptive pills (combination or pro-
gestin only), injectables (depot medroxyprogesterone acetate
or norethisterone enanthate), subdermal implant, IUD, ster-
ilization, condoms, supply methods (diaphragm, foam, or
jelly), lactational amenorrhea method (LAM), or emergency
contraception. LARC included subdermal implants and IUDs
while highly effective short-term reversible contraception
included oral contraceptive pills and injectables. LAM was
excluded from the highly effective short-term reversible
contraception because its effectiveness is limited to the first
six months postpartum and duration of method use was not
recorded for respondents. For women who reported using
more than one method, they were analyzed according to the
most effective method.
Descriptive statistics were used to compare character-
istics between women using modern contraceptive versus
those that were not. Percentages and frequencies or means
with standard deviation were calculated via Chi-square or
Wilcoxon tests and reported for categorical and continuous
measures, as appropriate. The percentage of women using
each individual method was calculated by survey year. For
women not using contraception, reasons were tabulated
by survey year. Among users of highly effective modern
conceptive methods, logistic regression was used to create
a predictive model for the odds of LARC versus short-
term contraception use (pills and injectables). We did not
compare those who reported LARC with those who reported
traditional or no method because we wanted to understand
differences between those using highly effective modern
contraception. All covariates with a 𝑝 value < 0.05 were kept
in the model using backwards stepwise regression. Survey
year remained in the model regardless of 𝑝 value. Prevalence
trends over time were calculated using linear regression and
included chronological time in years as the independent
variable. Statistical analyses were conducted with Stata 13.1
(StataCorp, College Station, TX) and figureswere adjusted for
the complex sampling design.
3. Results and Discussion
Between November 2004 and September 2011, a total of 12
survey rounds were completed across Lusaka District. Of the
43,200 heads of households who participated, 37,141 (86%)
were female. Among these, 7,665 women were excluded for
the following reasons: being outside the 16–50-year age range
(𝑛 = 2,963), report of pregnancy at time of survey (𝑛 = 3,511),
and report of prior hysterectomy or onset of menopause
(𝑛 = 1,191). The trend in pregnancy was nonlinear, with
a low of 7% in 2004 and a high of 11% in 2008. Among
the 29,476 respondents who were eligible for this analysis,
17,605 (60%) reported using modern contraception (Table 1).
Women using modern contraception were more likely to
be under 30 years of age, be married, and have at least
one child. They were also more likely to report prior HIV
voluntary counseling and testing and perceive themselves at
risk for HIV. Over the survey period, infrequent sex was
the most frequently reported reason for not using modern
contraception (45.9%), followed by desire for pregnancy
(23.4%) and health concerns (14.9%) (Figure 1).
Reported modern contraceptive use increased signifi-
cantly between 2004 and 2011 (Figure 2). In 2004, 53% of
respondents endorsed using modern contraception with oral
contraceptive pills being the most popular method (28%)
followed by LAM (18%) and injectables (10%). By 2011, 64%
of respondents reported using modern contraception. Oral
contraceptive pills remained themost popularmethod (22%),
while the frequency of injectable use increased (19%) and
LAM use decreased (6%). Condom use also increased over
the survey period, from 4% to 7%. LARC use was reported
by less than 1% of respondents in 2004 but had increased
to 9% by 2011. Significant positive changes were observed
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Table 1: Demographic and socioeconomic characteristics of 16–50-year-old nonpregnant female heads of household by contraceptive status
in Lusaka District, Zambia, 2004–2011.
Women using modern
contraception
(𝑛 = 17,605)
Women not using modern
contraception
(𝑛 = 11,871)
𝑝 value
Age, % <0.0011
16–24 26.9 18.8
25–30 36.6 28.1
31–39 28.3 29.2
40–50 8.3 24.0
Education, % <0.0011
None 3.4 5.1
Primary 38.9 39.2
Secondary 57.7 55.7
Marital status, % <0.0011
Married/cohabitating 92.2 61.7
Single/divorced/widowed 7.8 38.3
Religion, % 0.5381
Christian 99.2 99.1
Other 0.8 0.9
Living children, mean (SD) 2.76 (0.02) 2.92 (0.03) <0.0012
None 4.1% 17.2% <0.0011
≥1 95.9% 82.8%
Socioeconomic statusa, % 0.0021
Low 40.5 42.2
Medium 39.3 36.6
High 20.2 21.2
Household decision maker, % <0.0011
Woman 61.4 72.4
Husband/male partner 22.4 14.9
Decision made jointly 16.0 11.7
Other 0.3 1.0
Voluntary counseling and testing, % <0.0011
Ever 79.2 59.5
Never 20.8 40.5
HIV knowledgeb, % <0.0011
All questions correct 68.5 64.6
Not all questions correct 31.5 35.4
HIV self-risk perception, % <0.0011
No risk 36.3 47.7
At risk 50.7 37.8
Unknown 13.0 14.5
Survey year, % <0.0011
2004 7.8 10.1
2005 15.1 20.1
2006 8.0 9.0
2007 26.3 25.0
2008 8.4 8.1
2010 8.9 6.6
2011 25.6 21.2
1
𝜒
2 test.
2Wilcoxon test.
aThe household wealth index was created using principal components analysis based on asset variables, electricity, energy source, type of floor, number of
rooms, and water and sanitation variables similar to the demographic and health surveys.
bAs in the 2007 Zambia Demographic and Health Survey, interviewees were considered to have comprehensive knowledge of HIV if they correctly answered
five questions about HIV transmission risk and so indicated that they knew that HIV cannot be transmitted through mosquitoes, HIV cannot be transmitted
by witchcraft, HIV transmission risk can be reduced through condom use, HIV transmission can be reduced by having one HIV-negative sex partner, and a
healthy-looking person can have HIV.
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Figure 1: Reasons for nonuse of modern contraception among
16–50-year-old nonpregnant female heads of household in Lusaka
District, Zambia, 2004–2011.
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Figure 2: Trends in contraceptive use among 16–50-year-old non-
pregnant female heads of household in Lusaka District, Zambia,
2004–2011.
for injectable, condom, and LARC use (Table 2). The greatest
increases in LARC use were observed in the final two years of
the survey (Figure 3).
Among respondents endorsing modern contraceptive
use, 12,964 women reported highly effective reversible con-
traception use (74%, Table 3). Of these, 12,098 (93%) reported
use of a short-term method (pills or injectables) and 866
(7%) reported use of LARC. Factors associated with LARC
use included having at least one child, having a higher
socioeconomic status, and participating in the survey in 2010
and 2011. Younger women and those with less education
were less likely to report LARC use. Marital status, religion,
and household decision maker were not predictive of highly
effective reversible contraception use (Table 3).
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Figure 3: Trends in long-acting reversible contraceptive use among
16–50-year-old nonpregnant female heads of household in Lusaka
District, Zambia, 2004–2011.
In this citywide repeated cross-sectional survey, we
observed significant increases in modern contraceptive use
generally and LARC use specifically over an eight-year
period. Predictors of LARC use included older age, higher
socioeconomic status, and survey year. Our findings suggest
that programmatic efforts were highly successful in expand-
ing FP services across Lusaka from 2004 to 2011, particularly
in their promotion of LARC prior to 2010-2011. These
population-level results are reassuring and consistent with
increases in contraception uptake observed within specific
health facilities [13].
We noted increased use of modern contraception over
the observation period, a trend consistent with population-
based surveys in Zambia. In the 2007 Zambia Demographic
and Health Survey (DHS), for example, 25% of women were
using a modern method, with pills, injectables, and LAM
most commonly reported. Less than 1% reported LARC
use [14]. By 2013-14, nearly one-third of female respondents
reported using modern contraception, with injectables, pills,
and subdermal implants being the most popular methods.
More than 5% reported LARC use countrywide, but condom
use remained steady at 4% [15]. Similar results have been
shown in East Africa [10].We observedmuch higher modern
contraceptive use, from a baseline prevalence of 53% in 2004
to 64% in 2011. This is likely due to greater resources and
higher concentration of FP initiatives in the nation’s capital
city, as compared to more rural and remote parts of the
country, including programs focused on expanding FP access
to HIV-infected women and their partners [16–19].
Perhaps themost noteworthy finding from this secondary
analysis was the increase in LARC use over the final rounds
of the survey. Although this study was designed to measure
impact of an HIV treatment program, rather than a specific
contraceptive roll-out, we believe that the major contributor
to this increased coveragewas a highly successful initiative led
by the Zambian Ministry of Health (MOH) and the Society
for Family Health (SFH). In an effort to rapidly expand
services for LARC counseling and placement, this program
trained and posted dedicated health providers in over 20
public health facilities starting November 2008 [13]. Over
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Table 2: Trends in contraceptive use and specific contraceptive method use among 16–50-year-old nonpregnant female heads of household
in Lusaka District, Zambia, 2004–2011.
Survey year % (95% CI) Linear trend
coefficient, 𝑝 value2004 2005 2006 2007 2008 2010 2011
No contraceptive use 42.8%(40.6, 45.0)
41.4%
(38.8, 44.0)
36.4%
(33.6, 39.2)
35.6%
(33.4, 37.7)
33.5%
(30.8, 36.1)
29.1%
(26.9, 31.4)
32.7%
(31.0, 34.3)
−1.6 (−1.9, −1.2),
<0.01
Traditional contraceptive use 4.0%(2.9, 5.1)
6.0%
(5.0, 7.0)
6.8%
(4.8, 8.9)
3.6%
(3.0, 4.2)
5.9%
(4.8, 7.0)
4.5%
(3.5, 5.5)
2.8%
(2.3, 3.4)
−0.4% (−0.5, −0.2),
<0.01
Modern contraceptive use 53.0%(50.7, 55.3)
52.3%
(49.7, 55.0)
56.6%
(54.4,
58.9)
60.6%
(58.6,
62.6)
60.4%
(57.4, 63.5)
66.3%
(64.2, 68.4)
63.9%
(62.3, 65.6)
1.9% (1.5, 2.3),
<0.01
Condoms 3.5%(2.5, 4.6)
4.5%
(3.7, 5.3)
5.3%
(4.4, 6.3)
6.2%
(5.4, 7.0)
5.8%
(4.7, 7.0)
7.0%
(5.6, 8.5)
6.7%
(5.7, 7.8)
0.4% (0.2, 0.6)
<0.01
Lactational amenorrhea 10.3%(8.1, 12.5)
10.2%
(8.9, 11.5)
10.6%
(7.8, 13.4)
11.8%
(10.5, 13.1)
12.5%
(10.1, 14.9)
7.9%
(6.4, 9.3)
6.3%
(5.1, 7.4)
−0.7% (−0.9, −0.4)
<0.01
Oral contraceptive pillsa 27.8%(26.0, 29.6)
27.2%
(25.4, 29.0)
27.8%
(24.6, 31.1)
27.7%
(26.2, 29.1)
27.4%
(24.4, 30.3)
23.6%
(20.5, 26.7)
22.8%
(21.6, 24.1)
−0.8% (−1.1, − 0.5)
0.08
Injectables 9.6%(8.2, 11.0)
8.5%
(7.3, 9.8)
11.6%
(9.4, 13.7)
13.7%
(12.5, 14.9)
13.4%
(11.1, 15.7)
21.5%
(19.2, 23.8)
18.6%
(17.5, 19.7)
1.6% (1.4, 1.8)
<0.01
Long-acting reversible
contraceptionb
0.7%
(0.2, 1.1)
0.9%
(0.6, 1.1)
0.5%
(0.2, 0.8)
0.8%
(0.6, 1.0)
0.7%
(0.3, 1.2)
5.1%
(3.8, 6.4)
8.7%
(7.8, 10.0)
1.3% (1.1, 1.4)
<0.01
Implant 0.0%(0, 0.3)
0.1%
(0.0, 0.2)
0.1 %
(0.0, 0.2)
0.1%
(0.0, 0.2)
0.0
(0.0, 0.0)
0%
(0.0, 0.0)
4.1%
(3.3, 4.9)
0.6% (0.4, 0.7)
<0.01
IUD 0.7 %(0.2, 1.1)
0.8%
(0.5, 1.0)
0.4%
(0.1, 0.7)
0.7%
(0.3, 1.1)
0.7%
(0.3, 1.1)
5.1%
(3.8, 6.4)
4.6%
(3.8, 5.3)
0.7% (0.6, 0.8)
<0.01
Sterilization 0.5%(0.0, 0.9)
0.8%
(0.4, 1.0)
0.6%
(0.1, 1.1)
0.4%
(0.2, 0.5)
0.5%
(0.1, 0.8)
0.9%
(0.4, 1.3)
0.6%
(0.3, 0.9)
0.0% (−0.0, 0.1)
0.76
Other 0.6%(0.0, 1.3)
0.3%
(0.1, 0.5)
0.2%
(0.0, 0.4)
0.1%
(0.0, 0.1)
0.0%
(0.0, 0.0)
0.3%
(0.1, 0.5)
0.2%
(0.1, 0.3)
−0.0% (−0.1, 0.1)
0.24
aOral contraceptive pills include both combination and progestin only pills.
bLong-acting reversible contraception includes subdermal implants and intrauterine devices.
the first 14 months, 33,609 women had initiated a long-acting
contraceptive method, including subdermal implants (𝑛 =
22,079, 66%) and IUD (𝑛 = 11,530, 34%). In addition,
the MOH and SFH introduced postpartum IUD insertion
in Lusaka in 2009, offering an additional opportunity for
LARC uptake [20]. That such a high proportion of women
still reported use of these methods several years later (i.e., in
2010 and 2011) is highly encouraging and suggests that LARC
use can be sustained.
We observed substantial changes in the contraceptive
method mix reported by women over the eight-year period.
Use of oral contraceptives and LAM decreased over time,
while use of injectables and LARC increased, particularly
in the final survey rounds. The monitoring of such trends
is important from a program perspective and can help to
ensure that contraceptive supplymeets ongoing demand [21].
In places like Zambia, understanding the uptake of specific
methods may also be important in light of recent contro-
versies around hormonal contraception and HIV. Although
the overall evidence remains weak, some studies have sug-
gested that hormonal contraception may be associated with
increased rates of HIV acquisition among HIV-uninfected
women and accelerated disease progression among women
already infected with HIV [22, 23]. Recent work has also
suggested that, among HIV-infected women on efavirenz,
an antiretroviral agent recommended as part of first-line
HIV treatment [24], certain contraceptive methods may be
rendered less effective because of drug-drug interactions [25–
28]. As new evidence emerges, population-level data about
FP method use can help identify individuals who may need
more specific method counseling and inform broader health
policies around contraception.
Our study is not without limitations. First, there were
several concerns inherent to the survey itself, which was
primarily designed to measure all-cause mortality at a pop-
ulation level. Our reliance on self-identified female heads of
household may have introduced selection biases, particularly
around past obstetrical history and future fertility intension.
Due to the nature of the questions, responses from male
household heads were excluded altogether from this sec-
ondary analysis. In addition, our sampling frame, based on
the year 2000 census, may not have fully represented the
increasing population of urban Lusaka [12]. Second, we relied
on participant self-report for our measures of contraceptive
prevalence and allowed respondents to select more than one
method. We did not ask about the duration of current FP
method use or previously used methods, which limited our
ability to further describe FP trends. We were also unable
to determine the impact of method switching, from nonuse
to use, from traditional to modern methods, or between
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Table 3: Predictors of long-acting reversible contraception use among 16–50-year-old nonpregnant female heads of household using highly
effective reversible contraception in Lusaka, Zambia, 2004–2011 (𝑁 = 12,964)$.
Women using
long-acting reversible
contraception+
(𝑛 = 866)
Percentage
Women using highly
effective short-term
reversible contraception∧
(𝑛 = 12,098)
Percentage
Univariable
OR (95% CI)
Multivariable
OR (95% CI)
Age∗
16–24 14.6% 25.8% 0.33 (0.25, 0.45) 0.46 (0.34, 0.61)
25–30 35.3% 37.3% 0.56 (0.42, 0.74) 0.66 (0.50, 0.89)
31–39 35.7% 28.5% 0.74 (0.57, 0.96) 0.80 (0.61, 1.04)
40–50 14.4% 8.5% 1 1
Education∗
None 2.8% 3.3% 0.70 (0.42, 1.18) 0.97 (0.57, 1.65)
Primary 27.2% 38.9% 0.58 (0.45, 0.74) 0.70 (0.56, 0.89)
Secondary 70.0% 57.8% 1 1
Marital status
Married/cohabitating 95.0% 94.8% 1.03 (0.72, 1.48)
Single/divorced/widowed 5.0% 5.2% 1
Religion
Christian 99.0% 99.2% 0.72 (0.26, 2/03)
Other 1.0% 0.8% 1
Living children, mean (SD) 3.04 (0.08) 2.76 (0.02) 1.11 (1.06, 1.17)
None 1.9% 2.8%
≥1 98.1% 97.2%
Socioeconomic status∗
Low 27.6% 39.3% 1 1
Medium 42.9% 40.5% 1.51 (1.20, 1.90) 1.02 (0.82, 1.25)
High 29.6% 20.2% 2.09 (1.59, 2.74) 1.42 (1.14, 1.78)
Household decision maker
Woman 64.8% 60.2% 1
Husband/male partner 21.2% 23.4% 0.84 (0.66, 1.07)
Decision made jointly 13.9% 16.1% 0.80 (0.63, 1.01)
Other 0.0% 0.03% 0.17 (0.02, 1.29)
Survey year∗
2004 2.0% 8.1% 0.94 (0.46, 1.92) 0.98 (0.48, 1.97)
2005 4.9% 15.2% 1.25 (0.83, 1.88) 1.27 (0.86, 1.89)
2006 1.5% 8.3% 0.70 (0.37, 1.33) 0.71 (0.38, 1.34)
2007 6.8% 26.5% 1 1
2008 2.0% 8.4% 0.94 (0.50, 1.78) 0.90 (0.48, 1.70)
2010 13.6% 8.9% 5.90 (3.96, 8.80) 5.50 (3.69, 8.35)
2011 69.2% 24.6% 10.91 (7.96, 14.95) 10.73 (7.87, 14.61)
Percentages and odds ratios adjusted for complex sampling
$Survey data from all years were appended into a single data set.
∗Included in multivariable model.
+Long-acting reversible contraception includes subdermal implants and intrauterine devices.
∧Highly effective short-term reversible contraception includes oral contraceptive pills and injectables. Lactational amenorrhea was excluded because duration
was not recorded as part of the survey.
various modern methods. As such, the observed increase in
LARC could reflect a favorable substitution effect or a true
increase in overall use. Third, it is difficult to attribute these
trends to specific strategies or initiatives within Lusaka at
the time of survey. More detailed information about service
utilization would have greatly enhanced this analysis, includ-
ing reasons why women selected one contraceptive method
over another. Fourth, we provide only limited comparisons
to contemporaneous DHS surveys in Zambia (i.e., 2007,
2013-2014). We noted small but important differences in
our source populations that could make such comparisons
difficult. When determining reasons for noncontraceptive
use, for example, marital status, pregnancy, menopause, and
history of hysterectomy were considered differently between
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our analysis and that of the DHS [29]. Finally, we recognize
that the external validity of this study may be limited because
our survey was only conducted in Lusaka. While we used
liberal eligibility criteria for inclusion into the parent study,
contraceptive use patterns likely vary between urban and
rural locations in Zambia.
4. Conclusions
Population-based assessments of contraceptive use, like the
one described in this report, provide important information
to guide FP program optimization and expansion. Ongoing
monitoring of contraceptive prevalence can help program
managers and policy makers match the conceptive supply to
ongoing demand. Properly designed surveys can also serve
as an evaluative framework for assessing new and promising
interventions to increase uptake and retention within FP
programs. Although the optimal timing and intensity of
such assessments are yet to be determined, they are a nec-
essary component for program improvement and should
be included in coordinated efforts to achieve the post-2015
development agenda.
Disclaimer
The contents of this paper are solely the responsibility of the
authors and do not necessarily represent the official views of
the funding agencies.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This study was supported by a multicountry grant to the Eliz-
abeth Glaser Pediatric AIDS Foundation from the U.S. Cen-
ters for Disease Control and Prevention (cooperative agree-
ment U62/CCU12354) through the President’s Emergency
Plan for AIDS Relief. Additional investigator salary or trainee
support was provided by the National Institutes of Health
(T32 HD075731, R24 TW007988, and R25TW009340). The
authors thank the study respondents and staff for their time
and the Zambian Ministry of Health for its ongoing support
of implementation and outcomes research.
References
[1] J. Cleland, A. Conde-Agudelo, H. Peterson, J. Ross, and A. Tsui,
“Contraception and health,” The Lancet, vol. 380, no. 9837, pp.
149–156, 2012.
[2] M. Greene, S. Joshi, and O. Robles, By Choice, not by Chance:
Family Planning, Human Rights, and Development, United
Nations Population Fund (UNFPA), New York, NY, USA, 2012.
[3] World Health Organization, Ensuring Human Rights in the
Provision of Contraceptive Information and Services: Guidance
and Recommendations, World Health Organization, Geneva,
Switzerland, 2014.
[4] S. Singh and J. E. Darroch, Adding It Up: Costs and Benefits of
Contraceptive Services—Estimates for 2012, Guttmacher Insti-
tute, United National Population Fund (UNFPA), New York,
NY, USA, 2012.
[5] S. A. Cohen, “London Summit puts family planning back on
agenda, offers new lease on life formillions of women and girls,”
Guttmacher Policy Review, vol. 15, pp. 20–24, 2012.
[6] Family Planning 2020. Family Planning 2020, June 2015, http://
www.familyplanning2020.org/.
[7] World Health Organization Department of Reproductive
Health and Research (WHO/RHR) and Johns Hopkins Bloom-
berg School of Public Health/Center for Communication Pro-
grams (CCP) Knowledge for Health Project, Family Planning: A
Global Handbook for Providers (2011 Update), CCP, Baltimore,
Md, USA; WHO, Geneva, Switzerland, 2011.
[8] T. D. Ngo, O. Nuccio, K. Reiss, and S. K. Pereira, Expanding
Long-Acting and Permanent Contraceptive Use in Sub-Saharan
Africa to Meet FP2020 Goals, Marie Stopes International, Lon-
don, UK, 2013.
[9] J. W. Townsend, R. Sitruk-Ware, K. Williams, I. Askew, and K.
Brill, “New strategies for providing hormonal contraception in
developing countries,”Contraception, vol. 83, no. 5, pp. 405–409,
2011.
[10] J. E. Darroch and S. Singh, “Trends in contraceptive need and
use in developing countries in 2003, 2008, and 2012: an analysis
of national surveys,” The Lancet, vol. 381, no. 9879, pp. 1756–
1762, 2013.
[11] M. J. Giganti, J. W. Levy, Y. Banda et al., “Methods and baseline
results of a repeated cross-sectional survey to assess the public
health impact of antiretroviral therapy in Lusaka, Zambia,”
American Journal of Tropical Medicine and Hygiene, vol. 82, no.
5, pp. 971–977, 2010.
[12] S. D. Rathod, B. H. Chi, T. Kusanthan et al., “Trends in all-
cause mortality during the scale-up of an antiretroviral therapy
programme: a cross-sectional study in Lusaka, Zambia,”Bulletin
of the World Health Organization, vol. 92, no. 10, pp. 734–741,
2014.
[13] J. Neukom, J. Chilambwe, J. Mkandawire, R. K. Mbewe, and D.
Hubacher, “Dedicated providers of long-acting reversible con-
traception: new approach in Zambia,”Contraception, vol. 83, no.
5, pp. 447–452, 2011.
[14] Central Statistical Office (CSO), Ministry of Health (MOH),
Tropical Diseases Research Centre (TDRC), University of Zam-
bia, and Macro International, Zambia Demographic and Health
Survey 2007, Macro International, Calverton, Md, USA, 2009.
[15] Central Statistics Office (CSO) [Zambia], Ministry of Health
(MOH) [Zambia], and ICF International, Zambia Demographic
andHealth Survey 2013-2014, Central Statistical Office,Ministry
of Health, and ICF International, Rockville, Md, USA, 2014.
[16] C. J. Chibwesha, M. S. Li, C. K. Matoba et al., “Modern con-
traceptive and dual method use amongHIV-infected women in
Lusaka, Zambia,” Infectious Diseases in Obstetrics and Gynecol-
ogy, vol. 2011, Article ID 261453, 8 pages, 2011.
[17] K. Grabbe, R. Stephenson, B. Vwalika et al., “Knowledge, use,
and concerns about contraceptive methods among sero-dis-
cordant couples in Rwanda and Zambia,” Journal of Women’s
Health, vol. 18, no. 9, pp. 1449–1456, 2009.
[18] K. E. Mark, J. Meinzen-Derr, R. Stephenson et al., “Contracep-
tion amongHIV concordant and discordant couples in Zambia:
a randomized controlled trial,” Journal of Women’s Health, vol.
16, no. 8, pp. 1200–1210, 2007.
8 BioMed Research International
[19] A. Disha,M. Bwembya, E. Collins, P. Papworth, and E. Ronnow,
“Zambia: family planning quantitative and qualitative logis-
tics system assessment,” Task Order 1, USAID—DELIVER
PROJECT, Arlington, Va, USA, 2008.
[20] S. Prager, P. Gupta, J. Chilambwe et al., “Feasibility of training
Zambian nurse-midwives to perform postplacental and post-
partum insertions of intrauterine devices,” International Journal
of Gynecology and Obstetrics, vol. 117, no. 3, pp. 243–247, 2012.
[21] E. E. Seiber, J. T. Bertrand, and T. M. Sullivan, “Changes in con-
traceptive method mix in developing countries,” International
Family Planning Perspectives, vol. 33, no. 3, pp. 117–123, 2007.
[22] C. B. Polis, S. J. Phillips, K. M. Curtis et al., “Hormonal con-
traceptive methods and risk of HIV acquisition in women: a
systematic review of epidemiological evidence,” Contraception,
vol. 90, no. 4, pp. 360–390, 2014.
[23] S. J. Phillips, C. B. Polis, and K. M. Curtis, “The safety of hor-
monal contraceptives for women living with HIV and their
sexual partners,” Contraception, 2015.
[24] World Health Organization, Consolidated Guidelines on the Use
of Antiretroviral Drugs for Treating and Preventing HIV Infec-
tion, World Health Organization, Geneva, Switzerland, 2013.
[25] S. H. Perry, P. Swamy, G. A. Preidis, A. Mwanyumba, N. Motsa,
andH. N. Sarero, “Implementing the Jadelle implant for women
living with HIV in a resource-limited setting: concerns for drug
interactions leading to unintended pregnancies,” AIDS, vol. 28,
no. 5, pp. 791–793, 2014.
[26] N. K. Landolt, N. Phanuphak, S. Ubolyam et al., “Efavirenz,
in contrast to nevirapine, is associated with unfavorable pro-
gesterone and antiretroviral levels when coadministered with
combined oral contraceptives,” Journal of Acquired Immune
Deficiency Syndromes, vol. 62, no. 5, pp. 534–539, 2013.
[27] S. Y. El-Ibiary and J. M. Cocohoba, “Effects of HIV antiretro-
virals on the pharmacokinetics of hormonal contraceptives,”
European Journal of Contraception and Reproductive Health
Care, vol. 13, no. 2, pp. 123–132, 2008.
[28] J. A. Robinson, R. Jamshidi, and A. E. Burke, “Contraception
for the HIV-positive woman: a review of interactions between
hormonal contraception and antiretroviral therapy,” Infectious
Diseases in Obstetrics and Gynecology, vol. 2012, Article ID
890160, 15 pages, 2012.
[29] MEASURE DHS/ICF International, Demographic and Health
Surveys Methodology: Standard Recode Manual for DHS 6.
Demographic and Health Survey Toolkit of Methodology for the
MEASURE DHS Phase III (2008–2013), MEASURE DHS/ICF
International, Washington, DC, USA, 2013.
